Interested in your comments and trying better to understand an area that is foreign to me, and complicated. You say that Illumina have a panel test TSO500 that clinicians use all the time - but I think this site indicates it is only currently available for Research use?
https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=c8606ce8-c9ec-4c7f-9659-270952ae7bba
There also seems to be some debate about the sensitivity of the Grail test at this site:
https://www.annalsofoncology.org/article/S0923-7534(20)39870-7/fulltext.
Trying to gauge how Bard might stack up against competitors like Grail is probably too difficult for someone with my lack of medical expertise - but if Grail went for US$8b, the risk versus reward looks OK and I'm more familiar with balancing risk and reward.
Grail deal....BD1 is going to fly, page-17
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
63.0¢ |
Change
0.045(7.69%) |
Mkt cap ! $69.47M | |||
| Open | High | Low | Value | Volume |
| 58.5¢ | 63.5¢ | 58.5¢ | $149.7K | 242.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 858 | 63.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |